Abbonarsi

ANTIMICROBIAL PHARMACODYNAMICS - 06/09/11

Doi : 10.1016/S0025-7125(05)70296-0 
Paul G. Ambrose, PharmD a, Robert C. Owens, PharmD b, Dennis Grasela, PharmD, PhD c
a University of the Pacific School of Pharmacy, Stockton, California; Kendle International Inc, Princeton, New Jersey (PGA) 
b Department of Infectious Diseases, Maine Medical Center, Portland, Maine; the University of Vermont, College of Medicine, Burlington, Vermont (RCO) 
c Department of Clinical Pharmacology, Bristol-Myers Squibb, Princeton, New Jersey (DG) 

Riassunto

In his address to the American Association for the Advancement of Science in 1961, Leake30 delineated the fundamental issues of pharmacology: the dose and pharmacologic response relationship; the identification of the site of drug action; the mechanisms of action of a drug; the absorption, distribution, metabolism, and excretion of a drug; and the chemical structure and biologic activity relationship.43 An understanding of these pharmacologic issues forms the basis of modern chemotherapeutics. Since the dawn of modern antimicrobial therapy in the 1940s, a plethora of anti-infective compounds have been developed; their mechanisms of action determined; knowledge of their absorption, distribution, metabolism, and excretion elucidated; and their structure-activity relationships established. Since the introduction of penicillin, however, controversy regarding how antimicrobial agents should be administered to maximize the killing of microorganisms has existed.

One early approach described to determine the frequency of the dosing interval for an antimicrobial agent was to multiply the agent's serum half-life by a factor of 4 or 5. The dose itself was the result merely of trial and error. What occurred over a period of time beginning after the introduction of penicillin is what has been termed the 500 mg every 6 hours era by Craig. During this period, antimicrobial agents, regardless of half-life ranging from 0.5 hours to 8 hours, were dosed at 500 mg every 6 hours. This approach to dose and dosing interval selection was used for most antimicrobial agents that were developed for several decades, regardless of pharmacologic class, mechanism of action, or mode of bacterial killing.

This approach prevailed despite the observations of Eagle et al18, 19, 20 in the 1940s and 1950s that the total dose of penicillin necessary to cure syphilitic and streptococcal infection was considerably lower if the drug was administered continuously over 24 hours, rather than by intermittent injection. Eagle et al identified that for penicillin, the primary determinant of efficacy was the duration of time the bacteria were exposed to it. These observations contrasted sharply with those made regarding streptomycin and bacitracin, in which the magnitude of the concentrations of these drugs relative to the minimum inhibitory concentration (MIC) of the microorganism was found to be the determinant of efficacy.19

Contemporary data have accumulated from in vitro models of infection, animal models of infection, human volunteer experiments, and clinical trials that have confirmed and expanded on the observations of Eagle et al. Bacterial killing may be described as a function of drug concentration and time of exposure. The product of these pharmacokinetic measures is the area under the serum concentration-versus-time curve (AUC). Over clinically obtainable drug concentrations, simplifying assumptions can be made so that either drug concentration or time of drug exposure is of primary importance. When these assumptions cannot be made, however, both drug concentration and the time of drug exposure must be considered (e.g., the AUC). This knowledge has enabled clinicians finally to establish the best modes of antibiotic administration to maximize the killing of microorganisms.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Address reprint requests to Paul G. Ambrose, PharmD, 3757 Windridge Drive, Doylestown, PA 18901


© 2000  W. B. Saunders Company. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 84 - N° 6

P. 1431-1446 - novembre 2000 Ritorno al numero
Articolo precedente Articolo precedente
  • ANTIBIOTIC RESISTANCE
  • Burke A. Cunha
| Articolo seguente Articolo seguente
  • CLINICAL USE OF THE FLUOROQUINOLONES
  • Robert C. Owens, Paul G. Ambrose

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.